AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12855386 — intervention group
Group type: COMPARATOR
Intervention: Version 2 (attributed lower forecast income of women to extrinsic social learning factors)
Number of subjects: 100
Study 10493680 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels during attacks (FMF‐a)
Number of subjects: 30
Study 10493680 — intervention group
Group type: EXPERIMENTAL
Intervention: sICAM‐1 levels during remission (FMF‐r)
Number of subjects: 30
Study 10493680 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐8 levels during attacks (FMF‐a)
Number of subjects: 30
Study 10493680 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐8 levels during remission (FMF‐r)
Number of subjects: 30
Study 10493680 — intervention group
Group type: COMPARATOR
Intervention: sICAM‐1 levels in healthy controls (HC)
Number of subjects: 30
Study 10493680 — intervention group
Group type: COMPARATOR
Intervention: IL‐8 levels in healthy controls (HC)
Number of subjects: 30
Study 8730011 — intervention group
Group type: EXPERIMENTAL
Intervention: Exponential model
Number of subjects: 832
Study 8730011 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear model
Number of subjects: 832
Study 8730011 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapolated values (both models)
Number of subjects: 832
Study 2069776 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg caffeine
Number of subjects: 25
Study 6131080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 0.5 mg
Number of subjects: 0
Study 6131080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1.0 mg
Number of subjects: 0
Study 6131080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 1.5 mg
Number of subjects: 0
Study 6131080 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam 2.0 mg
Number of subjects: 0
Study 6131080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6131080 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal after lormetazepam
Number of subjects: 0
Study 30857523 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of reproductive health and available services
Number of subjects: 383
Study 29052344 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling after home-based HIV counselling and testing (HBHCT) at one and two months
Number of subjects: 302
Study 29052344 — intervention group
Group type: COMPARATOR
Intervention: Control group (HBHCT and referral only)
Number of subjects: 302
Study 29052344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 302
Study 26096318 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-Based Mirror Therapy (TBMT)
Number of subjects: 33
Study 26096318 — intervention group
Group type: COMPARATOR
Intervention: Standard motor rehabilitation
Number of subjects: 33
Study 25162920 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of autologous leukoreduced blood stored for 40 days
Number of subjects: 14
Study 25162920 — intervention group
Group type: COMPARATOR
Intervention: Transfusion of autologous leukoreduced blood stored for 3 days
Number of subjects: 14
Study 25162920 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 40-day blood while breathing 80 ppm nitric oxide
Number of subjects: 14
Study 21937893 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity specific exercise program
Number of subjects: 82
Study 21937893 — intervention group
Group type: COMPARATOR
Intervention: Walking program
Number of subjects: 82
Study 21937893 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 82
Study 19737441 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg mecamylamine
Number of subjects: 12
Study 19737441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17691588 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron(III)-hydroxide polymaltose complex (IPC, Maltofer) with tetracycline (2 x 250 mg capsules)
Number of subjects: 22
Study 17691588 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline alone (2 x 250 mg capsules)
Number of subjects: 22
Study 12576956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (6 mg/hr continuous infusion for 60 mins)
Number of subjects: 36
Study 12576956 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline, 6 mL/hr continuous infusion)
Number of subjects: 36
Study 10230810 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus flavonoid supplementation (about 1g/day, 3 weeks)
Number of subjects: 40
Study 10230810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8723850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam (5 mg)
Number of subjects: 4
Study 8723850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diazepam (10 mg)
Number of subjects: 4
Study 8723850 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam (7.5 mg)
Number of subjects: 4
Study 8723850 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam (30 mg)
Number of subjects: 4
Study 8723850 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular midazolam and diazepam
Number of subjects: 4
Study 1678203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin 5 mg/day
Number of subjects: 28
Study 1678203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6219149 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 0
Study 6219149 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 31013851 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CW (300 mg/d)
Number of subjects: 84
Study 31013851 — intervention group
Group type: COMPARATOR
Intervention: High-dose CW (600 mg/d)
Number of subjects: 84
Study 28601822 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop on decluttering and organising plus a visit from a professional cleaning company.
Number of subjects: 60
Study 28601822 — intervention group
Group type: COMPARATOR
Intervention: Control group (only visit from a professional cleaning company).
Number of subjects: 60
Study 26753640 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed extended-release formulation containing alpha-benzopyrone (Coumarin), benzo-gamma-pyrone (Troxuretina), and oligomeric proanthocyanidins from Vitis vinifera (OPC) in addition to compression therapy
Number of subjects: 0
Study 26753640 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy with manual lymphatic drainage and compression)
Number of subjects: 0
Study 23164597 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 35
Study 23164597 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 35
Study 20825373 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly severity ratings of manic symptoms
Number of subjects: 236
Study 20825373 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly severity ratings of depressive symptoms
Number of subjects: 236
Study 19325997 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 microg oral alphacalcidol twice daily for 6 months
Number of subjects: 19
Study 19325997 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study 16825679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oils (4 g/d)
Number of subjects: 48
Study 16825679 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 48
Study 16825679 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fish oils and Atorvastatin
Number of subjects: 48
Study 16825679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15039131 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal thoracic arteries from patients with LMS
Number of subjects: 74
Study 15039131 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial arteries from patients with LMS
Number of subjects: 74
Study 15039131 — intervention group
Group type: EXPERIMENTAL
Intervention: Long saphenous veins from patients with LMS
Number of subjects: 74
Study 15039131 — intervention group
Group type: COMPARATOR
Intervention: Internal thoracic arteries from patients with non-LMS
Number of subjects: 74
Study 15039131 — intervention group
Group type: COMPARATOR
Intervention: Radial arteries from patients with non-LMS
Number of subjects: 74
Study 15039131 — intervention group
Group type: COMPARATOR
Intervention: Long saphenous veins from patients with non-LMS
Number of subjects: 74
Study 10614892 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted management of warfarin therapy
Number of subjects: 100
Study 10614892 — intervention group
Group type: COMPARATOR
Intervention: Control group (physician-based management)
Number of subjects: 100
Study 8943961 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with esophageal stricture
Number of subjects: 57
Study 8943961 — intervention group
Group type: COMPARATOR
Intervention: Matched controls with esophagitis
Number of subjects: 57
Study 8943961 — intervention group
Group type: EXPERIMENTAL
Intervention: Stricture patients
Number of subjects: 57
Study 2018816 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP
Number of subjects: 12
Study 2018816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2018816 — intervention group
Group type: COMPARATOR
Intervention: Metergoline
Number of subjects: 12
Study 2018816 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline plus m-CPP
Number of subjects: 12
Study 2018816 — intervention group
Group type: COMPARATOR
Intervention: Metergoline pretreatment
Number of subjects: 12
Study 6983315 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (1 mg/kg)
Number of subjects: 18
Study 6983315 — intervention group
Group type: COMPARATOR
Intervention: Halothane and oxygen
Number of subjects: 18
Study 31138278 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based randomized controlled trials (COPTR consortium)
Number of subjects: 1745
Study 31138278 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies including careful planning, working with community partners, hiring culturally sensitive staff, and repeated contacts with potential participants
Number of subjects: 1745
Study 31138278 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year commitment to the trial
Number of subjects: 1745
Study 30301252 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 0
Study 30301252 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICIs)
Number of subjects: 0
Study 30301252 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SRS and ICIs
Number of subjects: 0
Study 26997655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose VPA (800 mg/day)
Number of subjects: 36
Study 26997655 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose VPA (1200 mg/day)
Number of subjects: 36
Study 26997655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24586256 — intervention group
Group type: EXPERIMENTAL
Intervention: TRC150094 (50 mg once daily)
Number of subjects: 40
Study 22696883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision surgical technique distal to the flexor crease (Group 1)
Number of subjects: 90
Study 22696883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision surgical technique proximal to the flexor crease (Group 2)
Number of subjects: 90
Study 20061421 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + Ox 0.03 mg/kg . d
Number of subjects: 133
Study 20061421 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + Ox 0.06 mg/kg . d
Number of subjects: 133
Study 20061421 — intervention group
Group type: COMPARATOR
Intervention: GH + Pl
Number of subjects: 133
Study 18052700 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam, 15 mg daily for 4 days starting the day before surgery
Number of subjects: 100
Study 18052700 — intervention group
Group type: COMPARATOR
Intervention: Tenoxicam, 20 mg daily for 4 days starting the day before surgery
Number of subjects: 100
Study 18052700 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Meloxicam and Tenoxicam)
Number of subjects: 100
Study 16037892 — intervention group
Group type: COMPARATOR
Intervention: Dehydration (2.1% to 2.6% body mass loss)
Number of subjects: 6
Study 12105159 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT-positive patients
Number of subjects: 310
Study 12105159 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPG 0/1
Number of subjects: 310
Study 12105159 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPG 0/1 flow
Number of subjects: 310
Study 11692346 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 88
Study 11692346 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water spray)
Number of subjects: 88
Study 8626879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone
Number of subjects: 8
Study 8626879 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 8
Study 2239934 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) therapy for 18 +/- 6 weeks
Number of subjects: 8
Study 2239934 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (r‐HuEPO) therapy
Number of subjects: 8
Study 31473505 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal, Ready-to-Eat (MRE) diet for 21 days followed by usual diet for 10 days
Number of subjects: 60
Study 31473505 — intervention group
Group type: COMPARATOR
Intervention: Control group consuming usual ad libitum diet for 31 days
Number of subjects: 60
Study 27867128 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 2 g every 8 hours
Number of subjects: 82
Study 27867128 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 hours
Number of subjects: 82
Study 27867128 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 6 hours
Number of subjects: 82
Study 25849469 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine in conjunction with lidocaine in intraligamentary injection
Number of subjects: 0
Study 25849469 — intervention group
Group type: COMPARATOR
Intervention: Control group (lidocaine alone)
Number of subjects: 0
Study 24205050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (nutrition education and physical activity)
Number of subjects: 8301
Study 24205050 — intervention group
Group type: COMPARATOR
Intervention: Control group (shared common control for nutrition and PA)
Number of subjects: 8301
Study 24205050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 8301
Study 24205050 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 8301
Study 24205050 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 8301
Study 21480203 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Expressions group (n = 25)
Number of subjects: 40
Study 21480203 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group; n = 15)
Number of subjects: 40
Study 19057400 — intervention group
Group type: EXPERIMENTAL
Intervention: below-knee compression stockings
Number of subjects: 21
Study 19057400 — intervention group
Group type: COMPARATOR
Intervention: running socks
Number of subjects: 21
Study 16555941 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 ml of white wine daily
Number of subjects: 42
Study 15061993 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO (1.0 microg.kg(‐1).d(‐1) administered subcutaneously 6‐24 hours after chemotherapy for up to 14 days)
Number of subjects: 81
Study 15061993 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO
Number of subjects: 81
Study 15061993 — intervention group
Group type: COMPARATOR
Intervention: Control (non-rhTPO-treated cycle)
Number of subjects: 81
Study 11568579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy with argon plasma coagulation (TE(APC))
Number of subjects: 201
Study 11568579 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy (TE(Conv))
Number of subjects: 201
Study 9692103 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin (500 mg t.d.s.)
Number of subjects: 12
Study 9692103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg b.d.)
Number of subjects: 12
Study 7921859 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (F)
Number of subjects: 30
Study 7921859 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 30
Study 3167404 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine treatment with self-exposure instructions
Number of subjects: 49
Study 3167404 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure (1.3 hours) added to self-exposure instructions (3 hours) after 8 weeks
Number of subjects: 49
Study 31575823 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep friction massage (DFM) with varying pressures
Number of subjects: 10
Study 31575823 — intervention group
Group type: COMPARATOR
Intervention: Control session (no DFM)
Number of subjects: 10
Study 30106637 — intervention group
Group type: EXPERIMENTAL
Intervention: HIMRT (72 Gy in 2.4 Gy fractions over 6 weeks)
Number of subjects: 206
Study 30106637 — intervention group
Group type: COMPARATOR
Intervention: CIMRT (75.6 Gy in 1.8 Gy fractions over 8.4 weeks)
Number of subjects: 206
Study 30106637 — intervention group
Group type: EXPERIMENTAL
Intervention: HIMRT
Number of subjects: 206
Study 30106637 — intervention group
Group type: COMPARATOR
Intervention: CIMRT
Number of subjects: 206
Study 27777076 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Pill Bottles with antihypertensive medications and recordings of pharmacists' counseling
Number of subjects: 134
Study 27777076 — intervention group
Group type: COMPARATOR
Intervention: Usual care instructions with antihypertensive medications
Number of subjects: 134
Study 27777076 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking Pill Bottles
Number of subjects: 134
Study 26277680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU/month; n = 38)
Number of subjects: 68
Study 26277680 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (400 IU vitamin E/month; n = 30)
Number of subjects: 68
Study 24112259 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 190
Study 24112259 — intervention group
Group type: COMPARATOR
Intervention: Ureterorenoscopic (URS) manipulation
Number of subjects: 190
Study 20388201 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane-based chemotherapy (Carboplatin AUC5 and Docetaxel 75 mg/m2 administered intravenously in a 3-weekly schedule)
Number of subjects: 32
Study 18160502 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous fixation with a cannulated Acutrak screw
Number of subjects: 60
Study 18160502 — intervention group
Group type: COMPARATOR
Intervention: Immobilisation in a cast
Number of subjects: 60
Study 16840728 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive induction and consolidation treatment according to a single protocol for patients above age 60
Number of subjects: 361
Study 16840728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk cytogenetics
Number of subjects: 361
Study 16840728 — intervention group
Group type: EXPERIMENTAL
Intervention: Age above 70 years
Number of subjects: 361
Study 14564333 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated stent
Number of subjects: 50
Study 14564333 — intervention group
Group type: COMPARATOR
Intervention: Noncoated stent
Number of subjects: 50
Study 11018621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 mg or 100 mg)
Number of subjects: 254
Study 11018621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 11018621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 254
Study 9028183 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct complete excavation
Number of subjects: 116
Study 9028183 — intervention group
Group type: COMPARATOR
Intervention: Stepwise excavation
Number of subjects: 116
Study 1631174 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD0, KD1, KD2)
Number of subjects: 14
Study 1631174 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium depletion treatment (KD2)
Number of subjects: 14
Study 6386253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroquinidine (DQ) 300 mg t.i.d.
Number of subjects: 12
Study 6386253 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (D) 200 mg t.i.d.
Number of subjects: 12
Study 6386253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3842761 GG genotype in PR group
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4244809 GG genotype in PR group
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4244809 GG genotype compared to AA genotype
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3842761 GG/CC+CG in FIGO stage III‐IV
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4244809 GG/AA+AG in FIGO stage III‐IV
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs3842761 GG/CC+CG in serous adenocarcinoma subgroup
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4244809 GG/AA+AG in serous adenocarcinoma subgroup
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: rs7924316 GG/TT+TG in serous adenocarcinoma subgroup
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: TCT haplotype of rs3741206/rs3842761/rs7924316
Number of subjects: 181
Study 30672383 — intervention group
Group type: EXPERIMENTAL
Intervention: TC haplotype of rs3741206/rs3842761
Number of subjects: 181
Study 29413060 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioural Stress Management Programme (BCBSMP), 1 session per week for 7 weeks, each session lasting 120 minutes.
Number of subjects: 61
Study 29413060 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 61